Top NYC, NY Biotech Companies With Best Stability & Growth (132)

Investor Backing & Capital Strength: Fresh capital includes a $50M Series D on April 9, 2026 led by Boehringer Ingelheim and a 2025 Series C with Dassault Systèmes/Medidata to fund commercialization and platform scaling. Feedback suggests these transactions reflect strong external confidence and provide runway to advance regulatory and launch efforts.

Product Line Growth: Multiple FDA authorizations (Rejoyn in 2024; CT‑132 in 2025), positive Phase 3 data for CT‑155, and acquisition of Better Therapeutics’ assets expand the portfolio across psychiatry, neurology, and cardiometabolic conditions. A 2026 Ultrahuman partnership further extends migraine technology into adjacent offerings.

Strategic Partnerships: Multi‑year collaborations with Boehringer Ingelheim and Otsuka, plus ecosystem ties with Dassault Systèmes/Medidata and Ultrahuman, underpin development and prospective commercialization. These alliances distribute risk and provide capabilities and channels that many peers lack.

Diversified Revenue Streams: Non‑COVID portfolio momentum across oncology, vaccines, and cardiovascular is contributing, with Eliquis, Prevnar, Vyndaqel, and Seagen‑derived assets cited as growth drivers. This breadth helps offset the normalization of COVID products.

Cost & Operational Efficiency: Adjusted diluted EPS rose in 2025 versus 2024, attributed to cost realignment and mix. Ongoing cost‑saving and manufacturing optimization programs are intended to support margins through mid‑decade.

Future-Ready Strategy: Management highlights oncology and next‑generation assets, with Seagen’s ADC platform and pending data/approvals expected to support medium‑term growth. Pipeline catalysts into 2026 position the company for potential re‑acceleration if execution lands as planned.

Strong Revenue Growth: Reported total net revenue rose from $693.4 million in 2024 to about $1.27 billion in 2025, with Q4 2025 also showing strong year‑over‑year growth. Management guides 2026 revenue to roughly $1.59 billion, indicating continued expansion.

Customer Loyalty & Retention: Disclosed net revenue retention of approximately 126% and total remaining contract value exceeding $1.1 billion signal expanding multi‑year demand. These metrics indicate existing customers are increasing spend and extending commitments.

Strategic Partnerships: Multi‑year collaborations with major pharmas and health systems—including a three‑year, $200 million data/modeling agreement with AstraZeneca/Pathos and an expanded Merck collaboration—support growth in data licensing and AI applications. Partnerships with top‑tier sponsors evidence strong demand for the platform.

Strong Revenue Growth: 2025 results show total revenue increased meaningfully year over year, with software higher and drug‑discovery contributions expanding. Management also guides continued expansion into 2026 as measured by software ACV.

Strategic Partnerships: Large, multi‑target collaborations (e.g., with Novartis) and integrations with leading pharmas (e.g., Lilly) reinforce commercial traction and ecosystem reach. These relationships support both recurring software usage and potential milestone‑driven upside.

Future-Ready Strategy: Accelerating the shift from on‑premise to hosted licensing is intended to make revenue more predictable and better align recognition with contract value. 2026 priorities emphasize platform scaling, new offerings like predictive toxicology, and deeper partner integrations.

Investor Backing & Capital Strength: Raised a $372 million Series D on June 26, 2024 with strategic participation from Sanofi, bringing total financing to roughly $600M+. This level of capital is described as supporting headcount expansion, pipeline acquisitions, and platform build‑out.

Strategic Partnerships: Entered a first‑of‑its‑kind AI collaboration with Sanofi and OpenAI in May 2024, later highlighted by Sanofi in its filings. Additional Sanofi-linked licensing activity signals commercial traction and scale ambitions.

Product Line Growth: Created Bleecker Bio and signed a December 2025 deal to develop Lynk Pharma’s TYK2 inhibitor (milestones up to $605M) with a Phase 1 start targeted for H1 2026. Disclosed programs, including at least one in Phase 3, indicate an expanding internal portfolio.

Product Line Growth: Flatiron rolled out AI-powered Panoramic datasets across major tumor types and launched new hematology datasets built from 505k+ blood cancer records, expanding the breadth and depth of its offerings. Ongoing research acceptances and a peer-reviewed validation framework for AI-extracted oncology data indicate continued product maturation.

Market Expansion: The company reported tripling its global research network to 30+ institutions across Europe and Japan by mid‑2025 and highlighted multinational dataset launches, signaling a broader international footprint. Establishing a Raleigh‑Durham Life Sciences Hub further reflects geographic growth.

Strategic Partnerships: Collaborations to accelerate trial enrollment and enhance clinico‑genomic offerings (e.g., Massive Bio, Caris) and a renewed multi‑year collaboration with FDA support sustained external momentum. A long‑term partnership with Paradigm following the 2025 divestiture reinforces a partner‑led services approach around its core platform.

Market Expansion: Public materials indicate the network scaled from over 2,500 community sites in 2023 to 6,000+ research sites and 25+ sponsors across 50+ countries by April 2026. This sequential ramp across sites, sponsors, and geographies suggests continued expansion on both sides of the marketplace.

Strategic Partnerships: New and expanding collaborations—such as AbbVie oncology rollouts and integrations with RealTime eClinical Solutions and CRIO—point to growing demand-side traction and data connectivity. These relationships embed the platform into sponsor and site workflows, reinforcing usage and reach.

Innovation-Driven Growth: The company launched AI Site Selection and AI-powered patient pre-screening in 2025, with 2026 case posts highlighting time and cost savings on active studies. This product velocity and real-world application signal ongoing innovation tied to operational outcomes.

Market Expansion: The company is described as operating across many U.S. states with a growing clinic footprint and patient coverage, indicating broadening geographic and delivery reach. Public-facing expansion targets and multi-state service capacity reinforce an intent to continue scaling coverage.

Innovation-Driven Growth: Multiple FDA clearances over time for radiology AI tools are cited, including early regulatory wins and subsequent additions in chest imaging, supporting a narrative of continued product and regulatory progress. The combination of FDA-cleared AI with clinical workflows is positioned as a differentiator that can benefit from wider imaging-AI adoption tailwinds.

Strong Market Position & Advantage: A vertically integrated diagnostics-as-a-service approach that bundles equipment, workflows, radiologists, and AI is presented as a clear differentiator versus pure software vendors. This integrated, ambulatory/primary-care focus is repeatedly framed as an area of niche leadership and traction.

Strong Market Position & Advantage: First-in-class approvals for Revuforj across two acute leukemia subtypes and NCCN inclusion, together with Niktimvo’s novel CSF-1R mechanism in cGVHD, position the company at the forefront of these niches. First-mover status and rapid guideline uptake underpin a durable competitive foothold.

Strong Revenue Growth: Reported revenue increased sequentially in 2025 with rising Revuforj prescriptions and growing collaboration revenue from Niktimvo, signaling early commercial traction. Multiple new approvals and label expansions during 2024–2025 further supported the ramp.

Strategic Partnerships: Co-commercialization with Incyte enhances market penetration in cGVHD, and the World Orphan Drug Alliance program expands access to Revuforj globally. These alliances bolster commercial reach and operational execution.

Strong Revenue Growth: Recent results show a meaningful step‑up in 2025 revenue with double‑digit year‑over‑year growth and guidance pointing to continued double‑digit expansion into 2026. Feedback suggests performance was slightly ahead of prior guidance and supported by broad‑based demand across regions and customer segments.

Strong Market Position & Advantage: ONT is described as a clear leader in nanopore sequencing and a co‑leader in long‑reads, differentiated by portability, real‑time analysis, ultra‑long reads, and native DNA/RNA methylation detection. Flagship datasets and assemblies reinforce this positioning.

Market Expansion: Updates highlight accelerating adoption beyond academia into clinical, applied industrial and biopharma use cases, alongside growing high‑throughput deployments on PromethION. Feedback suggests growth was evident across major geographies and end‑markets with notable momentum in regulated and applied settings.